Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752197 | 0.83 | ATM (0.44) | KDM4EHTTLMNAMAPTATM | |
| SCHEMBL711918 | 0.81 | KDM4E (0.39) | KDM4EHTTLMNAMAPTATM | |
| SCHEMBL6587304 | 0.81 | ERN1 (0.43) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL7831700 | 0.80 | KDM4E (0.45) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL498998 | 0.78 | KDM4E (0.44) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL6698426 | 0.76 | KDM4E (0.42) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL655887 | 0.75 | HPGD (0.46) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL8560175 | 0.74 | HTT (0.41) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL9463701 | 0.74 | KDM4E (0.40) | KDM4EHPGDHTTLMNAMAPT | |
| SCHEMBL9016431 | 0.74 | KDM4E (0.43) | KDM4EHPGDHTTLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-5264436-A | Alpha-adrenoceptors antagonist, hypotensive agents or antidiabetic agents | BEECHAM GROUP P.L.C. (GB) | 1993-11-23 | — | — | US | disclosed |
| EP-0275639-B1 | N-SUBSTITUTED CYCLIC AMIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1992-07-15 | — | — | EP | disclosed |
| US-5077299-A | Glaucoma, antidepressants, anticoagulants, hypotensive agents | BEECHAM GROUP P.L.C. (GB) | 1991-12-31 | — | — | US | disclosed |
| US-4918083-A | 4,5 Dihydroimidazole compounds which have useful pharmaceutical utility | BEECHAM GROUP P.L.C. (GB) | 1990-04-17 | — | — | US | disclosed |
| EP-0275639-A1 | N-substituted cyclic amides, their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | XDH 3256/4885KDM4E 2117/4885HPGD 1805/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | XDH 661/4885KDM4E 4057/4885HPGD 2802/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | XDH 636/4885KDM4E 4100/4885HPGD 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.